Clinical Scorecard: Case Study: Innovative TKI Combination Approaches for EGFR-Mutated NSCLC with Acquired ROS1 Fusion and Cerebral Metastases

At a Glance

Key Highlights

• Patient achieved over 6.5 years of survival with dynamic therapy adjustments, including specific details on initial response to osimertinib.
• Initial treatment with osimertinib led to significant lesion shrinkage, with details on adverse reactions.
• Subsequent treatments included crizotinib, entrectinib, and lorlatinib, with emphasis on their distinct side effect profiles.
• Reintroduction of crizotinib and entrectinib was well-tolerated after initial adverse reactions, highlighting the importance of monitoring.

Guideline-Based Recommendations

Diagnosis

Management

• Sequential treatment with targeted therapies based on individual response, including specific strategies for managing resistance.

Monitoring & Follow-up

Risks

Patient & Prescribing Data

Dynamic adjustments to therapy were crucial for managing disease progression, impacting overall survival.

Clinical Best Practices

• Consider combination therapies for patients with complex co-mutations, emphasizing the need for individualized treatment plans.
• Monitor for adverse effects closely when using TKIs, with specific examples from the case.
• Utilize imaging and molecular testing to guide treatment decisions, ensuring alignment with patient-specific factors.

Related Resources & Content